---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-039023"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:38:41.567620+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics appoints Steve Fawell to board; Malcolm Salter retires after nearly a decade

## Summary
- Malcolm Salter resigned from board effective August 29, 2024, after ~9 years; no disagreements.
- Stephen Fawell, Ph.D. appointed as Class III director through 2026 annual meeting; granted 65,000 share options.
- Fawell has 35 years drug discovery experience, most recently VP head of oncology small molecule discovery at AstraZeneca.
- Ronald Cooper appointed chair of Nominating and Corporate Governance Committee; Bruce Downey added to Audit Committee.

## SEC filing metadata
- accession: 0001628280-24-039023
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024039023/0001628280-24-039023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024039023/cccc-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-039023
- JSON: https://secwatch.observer/filing/0001628280-24-039023.json
- Plain text: https://secwatch.observer/filing/0001628280-24-039023.txt

## Key facts
- Executive change
  Malcolm Salter resigned as Director at C4 Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 28, 2024, Malcolm Salter informed the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to resign from the Board, effective upon the appointment of his successor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024039023/0001628280-24-039023-index.htm
- Executive change
  Stephen Fawell was appointed as Director at C4 Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 29, 2024, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Stephen Fawell, Ph.D. as a director of the Company and a member of the Science and Technology Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024039023/0001628280-24-039023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.